» Articles » PMID: 33916317

MicroRNA Expression Profile Distinguishes Glioblastoma Stem Cells from Differentiated Tumor Cells

Overview
Journal J Pers Med
Date 2021 Apr 30
PMID 33916317
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma (GBM) represents the most common and aggressive tumor of the brain. Despite the fact that several studies have recently addressed the molecular mechanisms underlying the disease, its etiology and pathogenesis are still poorly understood. GBM displays poor prognosis and its resistance to common therapeutic approaches makes it a highly recurrent tumor. Several studies have identified a subpopulation of tumor cells, known as GBM cancer stem cells (CSCs) characterized by the ability of self-renewal, tumor initiation and propagation. GBM CSCs have been shown to survive GBM chemotherapy and radiotherapy. Thus, targeting CSCs represents a promising approach to treat GBM. Recent evidence has shown that GBM is characterized by a dysregulated expression of microRNA (miRNAs). In this study we have investigated the difference between human GBM CSCs and their paired autologous differentiated tumor cells. Array-based profiling and quantitative Real-Time PCR (qRT-PCR) were performed to identify miRNAs differentially expressed in CSCs. The Cancer Genome Atlas (TCGA) data were also interrogated, and functional interpretation analysis was performed. We have identified 14 miRNAs significantly differentially expressed in GBM CSCs ( < 0.005). MiR-21 and miR-95 were among the most significantly deregulated miRNAs, and their expression was also associated to patient survival. We believe that the data provided here carry important implications for future studies aiming at elucidating the molecular mechanisms underlying GBM.

Citing Articles

Urinary miRNAs: Technical Updates.

Raveendran S, Al Massih A, Al Hashmi M, Saeed A, Al-Azwani I, Mathew R Microrna. 2024; 13(2):110-123.

PMID: 38778602 DOI: 10.2174/0122115366305985240502094814.


Exploring the Role of microRNAs in Glioma Progression, Prognosis, and Therapeutic Strategies.

Tluli O, Al-Maadhadi M, Al-Khulaifi A, Akomolafe A, Al-Kuwari S, Al-Khayarin R Cancers (Basel). 2023; 15(17).

PMID: 37686489 PMC: 10486509. DOI: 10.3390/cancers15174213.


microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)-Recent Literature Review.

Makowska M, Smolarz B, Romanowicz H Int J Mol Sci. 2023; 24(4).

PMID: 36834933 PMC: 9965735. DOI: 10.3390/ijms24043521.


Artificial Intelligence and Precision Medicine: A New Frontier for the Treatment of Brain Tumors.

Philip A, Samuel B, Bhatia S, Khalifa S, El-Seedi H Life (Basel). 2023; 13(1).

PMID: 36675973 PMC: 9866715. DOI: 10.3390/life13010024.


MicroRNA and mRNA Expression Changes in Glioblastoma Cells Cultivated under Conditions of Neurosphere Formation.

Dymova M, Vasileva N, Kuligina E, Savinovskaya Y, Zinchenko N, Ageenko A Curr Issues Mol Biol. 2022; 44(11):5294-5311.

PMID: 36354672 PMC: 9688839. DOI: 10.3390/cimb44110360.


References
1.
Khan A, Ahmed E, Elareer N, Junejo K, Steinhoff M, Uddin S . Role of miRNA-Regulated Cancer Stem Cells in the Pathogenesis of Human Malignancies. Cells. 2019; 8(8). PMC: 6721829. DOI: 10.3390/cells8080840. View

2.
Yao Q, Chen Y, Zhou X . The roles of microRNAs in epigenetic regulation. Curr Opin Chem Biol. 2019; 51:11-17. DOI: 10.1016/j.cbpa.2019.01.024. View

3.
Maccalli C, De Maria R . Cancer stem cells: perspectives for therapeutic targeting. Cancer Immunol Immunother. 2014; 64(1):91-7. PMC: 11028671. DOI: 10.1007/s00262-014-1592-1. View

4.
Eyler C, Rich J . Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008; 26(17):2839-45. PMC: 2739000. DOI: 10.1200/JCO.2007.15.1829. View

5.
Maccalli C, Parmiani G, Ferrone S . Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy. Immunol Invest. 2017; 46(3):221-238. DOI: 10.1080/08820139.2017.1280051. View